Nikita Malakhov1, Anna Lee2, Elizabeth Garay3, Daniel J Becker4, David Schreiber5. 1. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York, USA. 2. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York, USA; Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, USA. Electronic address: anna.lee@downstate.edu. 3. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York, USA; Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, USA. 4. Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, USA; Department of Medical Oncology, NYU School of Medicine, New York, NY, USA. 5. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, New York, USA; Summit Medical Group MD Anderson Cancer Center, Berkeley Heights, NJ, USA.
Abstract
PURPOSE/ OBJECTIVES: While treatment with tumor resection followed by chemoradiation is generally the accepted standard of care for glioblastoma (GBM), the treatment for patients with poor performance status remains uncertain. Therefore we sought to examine patterns of care and survival outcomes among patients with poor performance status utilizing a large hospital database. METHODS/MATERIALS: We queried the National Cancer Database (NCDB) for patients with GBM and Karnofsky performance status (KPS) <60 between 2010 and 2013. Data was collected regarding surgery, radiation therapy and chemotherapy. Logistic regression was used to analyze predictors for utilization of chemoradiation. The Kaplan-Meier method was used to compare survival between those who received chemoradiation to radiation alone and Cox regression was performed to assess covariates associated with survival. RESULTS: There were 488 patients included in the analysis of which 51.2% received chemoradiation and 46.1% underwent subtotal or gross total resection. None of the factors analyzed were significantly associated with increased likelihood of receiving chemoradiation over radiation alone. Survival data was available for 236 patients that received radiation therapy with and without combination chemotherapy. The median overall survival for those receiving radiation alone was 3.6 months and 8.7 months in those who received chemoradiation (p < 0.001). On multivariable Cox regression, increasing age (HR 1.80-2.10, p = 0.001) was associated with worse survival while subtotal/gross total resection (HR 0.60, p = 0.003) and chemoradiation (HR 0.57, CI 0.40-0.83, p = 0.003) were associated with improved survival. CONCLUSION: Even patients with poor performance status had better survival outcomes when they received treatment with chemoradiation over radiation alone.
PURPOSE/ OBJECTIVES: While treatment with tumor resection followed by chemoradiation is generally the accepted standard of care for glioblastoma (GBM), the treatment for patients with poor performance status remains uncertain. Therefore we sought to examine patterns of care and survival outcomes among patients with poor performance status utilizing a large hospital database. METHODS/MATERIALS: We queried the National Cancer Database (NCDB) for patients with GBM and Karnofsky performance status (KPS) <60 between 2010 and 2013. Data was collected regarding surgery, radiation therapy and chemotherapy. Logistic regression was used to analyze predictors for utilization of chemoradiation. The Kaplan-Meier method was used to compare survival between those who received chemoradiation to radiation alone and Cox regression was performed to assess covariates associated with survival. RESULTS: There were 488 patients included in the analysis of which 51.2% received chemoradiation and 46.1% underwent subtotal or gross total resection. None of the factors analyzed were significantly associated with increased likelihood of receiving chemoradiation over radiation alone. Survival data was available for 236 patients that received radiation therapy with and without combination chemotherapy. The median overall survival for those receiving radiation alone was 3.6 months and 8.7 months in those who received chemoradiation (p < 0.001). On multivariable Cox regression, increasing age (HR 1.80-2.10, p = 0.001) was associated with worse survival while subtotal/gross total resection (HR 0.60, p = 0.003) and chemoradiation (HR 0.57, CI 0.40-0.83, p = 0.003) were associated with improved survival. CONCLUSION: Even patients with poor performance status had better survival outcomes when they received treatment with chemoradiation over radiation alone.